Discovery of missing steps of secoiridoid pathway in Catharanthus roseus

Research output: Contribution to conferenceConference articleScientific

Abstract

Eukaryotes such as higher plants have evolved to produce a diverse range of low-molecular-weight secondary compounds that can be used as food and feed additives, flavours, fragrances, cosmetics, agrochemicals and pharmaceuticals. The dominant role of secondary metabolites in the pharmaceutical industry is demonstrated by the fact that approximately 50% of novel anticancer drugs have been discovered from nature including blockbusters such as taxanes (paclitaxel), terpenoid indole alkaloids and camptothecin. The chemical synthesis of plant-derived compounds is usually challenging and uneconomical because the complex stereospecific structures are difficult to replicate. Sustainable and cost-effective production systems must therefore be developed, and the best outcome can be achieved by integrating biotechnology-based approaches into more sustainable production chains featuring cutting-edge innovative technologies. Spectacular advances in characterizing plant metabolic pathways using functional genomics and through the development of large-scale cultivation processes have offered for the first time unprecedented opportunities to explore the extraordinary complexity of the biochemical capacity of plants in entirely new ways. State-of-the-art genomics tools can now be used to improve the production of known natural compounds or to synthesize entirely novel plant constituents by combinatorial biochemistry in cultivated plants and cells1. Therefore, the utilization of plants and cells as green production factories is becoming more realistic and more attractive also from a commercial point of view. Metabolic engineering aspects to discover bottlenecks in the complex biosynthetic pathways, and how the selected pathway can be directed towards the desired end-product will be highlighted using the discovery of missing enzymatic steps in the early seco-iridoid pathway as an example. Reference Rischer H, Häkkinen ST, Ritala A, Seppänen-Laakso T, Miralpeix B, Capell T, Christou P, Oksman-Caldentey K-M (2013): Plant cells as pharmaceutical factories. Curr Pharm Design 19: 5640-5660.
Original languageEnglish
Publication statusPublished - 2015
EventXI Reunión de la Sociedad Española de Cultivo In vitro de Tejidos Vegetales - Valencia, Spain
Duration: 3 Sep 20154 Sep 2015

Other

OtherXI Reunión de la Sociedad Española de Cultivo In vitro de Tejidos Vegetales
CountrySpain
CityValencia
Period3/09/154/09/15

Fingerprint

Catharanthus roseus
factories
biochemical pathways
taxanes
genomics
drugs
metabolic engineering
indole alkaloids
paclitaxel
antineoplastic agents
feed additives
agrochemicals
food additives
cosmetics
terpenoids
biochemistry
biotechnology
secondary metabolites
eukaryotic cells
production technology

Cite this

Oksman-Caldentey, K-M. (2015). Discovery of missing steps of secoiridoid pathway in Catharanthus roseus. Paper presented at XI Reunión de la Sociedad Española de Cultivo In vitro de Tejidos Vegetales, Valencia, Spain.
Oksman-Caldentey, Kirsi-Marja. / Discovery of missing steps of secoiridoid pathway in Catharanthus roseus. Paper presented at XI Reunión de la Sociedad Española de Cultivo In vitro de Tejidos Vegetales, Valencia, Spain.
@conference{b9dc2a4bf6164f1ca765cab3f6a3f125,
title = "Discovery of missing steps of secoiridoid pathway in Catharanthus roseus",
abstract = "Eukaryotes such as higher plants have evolved to produce a diverse range of low-molecular-weight secondary compounds that can be used as food and feed additives, flavours, fragrances, cosmetics, agrochemicals and pharmaceuticals. The dominant role of secondary metabolites in the pharmaceutical industry is demonstrated by the fact that approximately 50{\%} of novel anticancer drugs have been discovered from nature including blockbusters such as taxanes (paclitaxel), terpenoid indole alkaloids and camptothecin. The chemical synthesis of plant-derived compounds is usually challenging and uneconomical because the complex stereospecific structures are difficult to replicate. Sustainable and cost-effective production systems must therefore be developed, and the best outcome can be achieved by integrating biotechnology-based approaches into more sustainable production chains featuring cutting-edge innovative technologies. Spectacular advances in characterizing plant metabolic pathways using functional genomics and through the development of large-scale cultivation processes have offered for the first time unprecedented opportunities to explore the extraordinary complexity of the biochemical capacity of plants in entirely new ways. State-of-the-art genomics tools can now be used to improve the production of known natural compounds or to synthesize entirely novel plant constituents by combinatorial biochemistry in cultivated plants and cells1. Therefore, the utilization of plants and cells as green production factories is becoming more realistic and more attractive also from a commercial point of view. Metabolic engineering aspects to discover bottlenecks in the complex biosynthetic pathways, and how the selected pathway can be directed towards the desired end-product will be highlighted using the discovery of missing enzymatic steps in the early seco-iridoid pathway as an example. Reference Rischer H, H{\"a}kkinen ST, Ritala A, Sepp{\"a}nen-Laakso T, Miralpeix B, Capell T, Christou P, Oksman-Caldentey K-M (2013): Plant cells as pharmaceutical factories. Curr Pharm Design 19: 5640-5660.",
author = "Kirsi-Marja Oksman-Caldentey",
note = "Invited opening pleanary lecture; XI Reuni{\'o}n de la Sociedad Espa{\~n}ola de Cultivo In vitro de Tejidos Vegetales ; Conference date: 03-09-2015 Through 04-09-2015",
year = "2015",
language = "English",

}

Oksman-Caldentey, K-M 2015, 'Discovery of missing steps of secoiridoid pathway in Catharanthus roseus' Paper presented at XI Reunión de la Sociedad Española de Cultivo In vitro de Tejidos Vegetales, Valencia, Spain, 3/09/15 - 4/09/15, .

Discovery of missing steps of secoiridoid pathway in Catharanthus roseus. / Oksman-Caldentey, Kirsi-Marja.

2015. Paper presented at XI Reunión de la Sociedad Española de Cultivo In vitro de Tejidos Vegetales, Valencia, Spain.

Research output: Contribution to conferenceConference articleScientific

TY - CONF

T1 - Discovery of missing steps of secoiridoid pathway in Catharanthus roseus

AU - Oksman-Caldentey, Kirsi-Marja

N1 - Invited opening pleanary lecture

PY - 2015

Y1 - 2015

N2 - Eukaryotes such as higher plants have evolved to produce a diverse range of low-molecular-weight secondary compounds that can be used as food and feed additives, flavours, fragrances, cosmetics, agrochemicals and pharmaceuticals. The dominant role of secondary metabolites in the pharmaceutical industry is demonstrated by the fact that approximately 50% of novel anticancer drugs have been discovered from nature including blockbusters such as taxanes (paclitaxel), terpenoid indole alkaloids and camptothecin. The chemical synthesis of plant-derived compounds is usually challenging and uneconomical because the complex stereospecific structures are difficult to replicate. Sustainable and cost-effective production systems must therefore be developed, and the best outcome can be achieved by integrating biotechnology-based approaches into more sustainable production chains featuring cutting-edge innovative technologies. Spectacular advances in characterizing plant metabolic pathways using functional genomics and through the development of large-scale cultivation processes have offered for the first time unprecedented opportunities to explore the extraordinary complexity of the biochemical capacity of plants in entirely new ways. State-of-the-art genomics tools can now be used to improve the production of known natural compounds or to synthesize entirely novel plant constituents by combinatorial biochemistry in cultivated plants and cells1. Therefore, the utilization of plants and cells as green production factories is becoming more realistic and more attractive also from a commercial point of view. Metabolic engineering aspects to discover bottlenecks in the complex biosynthetic pathways, and how the selected pathway can be directed towards the desired end-product will be highlighted using the discovery of missing enzymatic steps in the early seco-iridoid pathway as an example. Reference Rischer H, Häkkinen ST, Ritala A, Seppänen-Laakso T, Miralpeix B, Capell T, Christou P, Oksman-Caldentey K-M (2013): Plant cells as pharmaceutical factories. Curr Pharm Design 19: 5640-5660.

AB - Eukaryotes such as higher plants have evolved to produce a diverse range of low-molecular-weight secondary compounds that can be used as food and feed additives, flavours, fragrances, cosmetics, agrochemicals and pharmaceuticals. The dominant role of secondary metabolites in the pharmaceutical industry is demonstrated by the fact that approximately 50% of novel anticancer drugs have been discovered from nature including blockbusters such as taxanes (paclitaxel), terpenoid indole alkaloids and camptothecin. The chemical synthesis of plant-derived compounds is usually challenging and uneconomical because the complex stereospecific structures are difficult to replicate. Sustainable and cost-effective production systems must therefore be developed, and the best outcome can be achieved by integrating biotechnology-based approaches into more sustainable production chains featuring cutting-edge innovative technologies. Spectacular advances in characterizing plant metabolic pathways using functional genomics and through the development of large-scale cultivation processes have offered for the first time unprecedented opportunities to explore the extraordinary complexity of the biochemical capacity of plants in entirely new ways. State-of-the-art genomics tools can now be used to improve the production of known natural compounds or to synthesize entirely novel plant constituents by combinatorial biochemistry in cultivated plants and cells1. Therefore, the utilization of plants and cells as green production factories is becoming more realistic and more attractive also from a commercial point of view. Metabolic engineering aspects to discover bottlenecks in the complex biosynthetic pathways, and how the selected pathway can be directed towards the desired end-product will be highlighted using the discovery of missing enzymatic steps in the early seco-iridoid pathway as an example. Reference Rischer H, Häkkinen ST, Ritala A, Seppänen-Laakso T, Miralpeix B, Capell T, Christou P, Oksman-Caldentey K-M (2013): Plant cells as pharmaceutical factories. Curr Pharm Design 19: 5640-5660.

M3 - Conference article

ER -

Oksman-Caldentey K-M. Discovery of missing steps of secoiridoid pathway in Catharanthus roseus. 2015. Paper presented at XI Reunión de la Sociedad Española de Cultivo In vitro de Tejidos Vegetales, Valencia, Spain.